Bristol-Myers Squibb’s recent immunotherapy combo won FDA approval for patients with a rare colon cancer. The combinational medicine was formulated between an older medicine named Yervoy and a new cancer-fighter Opdivo. This combo drug focuses on repairing the mismatch gene.
A study report published in Nature's Digital Medicine partner journal shows that the wearable monitor Fitbit Charge HR could assess the health condition of cancer patients and predict their adverse events.
Gilead’s Yescarta and Novartis’ Kymriah garnered a lot of interest among T-cell therapies after producing high response rates in patients with lymphoma and leukemia. However, the same has not been true for this technology in cases of solid tumors. In this novel procedure, patients’ immune-boosting T cells are extracted and engineered to target and destroy cancer cells.
The newly formed health insurance administration in China intend to deepen discounts on cancer drugs which were already on its National Reimbursement Drug List (NRDL) based on public bidding and procurement based on cancer therapies. In the meantime, officials will start enlisting negotiations for treatments which were not included on the coverage list.
More than 2.5 million people work night-shifts. In 2007, the International Agency for Research on Cancer (IARC) reported that working shifts generally disturbs momentum classified as being “probably carcinogenic to humans”.
Switzerland-based NBE Therapeutics AG, a biopharmaceutical company, announced a $20 million extension of series B funding led by Novo Holdings. Earlier in the series B funding round, the company had received $20 million, bringing the total funding to $40 million. The Swiss startup will use the new funding for the testing of the anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in patients with solid tumors.
The U.S, Based Array BioPharma received FDA approval for its much-awaited BRAFTOVI capsules with the combination of MEKTOVI tablets for the treatment of patients with metastatic melanoma with a BRAFV600E or BRAFV600K mutation.
RET-driven cancers include medullary and papillary thyroid cancer, non-small cell lung cancer, colorectal and bile duct cancer, which have been very difficult to treat till date. Chemotherapy has been the only available treatment but leads to multiple side effects.
To develop small molecules which can target RNA mis-splicing in neurological diseases, Celgene is launching a $60 million collaboration with Skyhawk Therapeutics. Celgene received the option to develop up to five drug molecules for correcting neurological diseases such as Huntington’s disease, amyotrophic lateral sclerosis etc. The $60 million payment includes milestones, license fees and royalties.
NBTXR3 is composed of crystalline nanoparticles to amplify the efficacy of radiation therapy. The idea is to administer NBTXR3 as intra-tumoral injections before external beam radiation therapy, thereby increasing the antitumor effect, and thus preparing the patient for surgical resection.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.